Search Results 691-700 of 21270 for platelets

  1. Ponatinib (oral route) - Side effects & dosage - Mayo Clinic

    Thrombocytopenia (low platelets in the blood)—Use with caution. ... It can also lower the number of platelets, which are necessary for proper blood clotting.

  2. Orthopedic Surgery - Doctors - Mayo Clinic

    Jelsing, M.D.. Sports Medicine Specialist. Rochester, MN. Areas of focus: Ultrasound, Platelet rich plasma injection, Soft tissue injection, Joint injection ...

  3. Physical Medicine and Rehabilitation - Doctors - Mayo Clinic

    ... Platelet... rich plasma injection, Prolotherapy, Bone marrow aspirate ... King, D.O.. Sports Medicine Specialist. Jacksonville, FL. Areas of focus: Platelet ...

  4. Jay Smith Archives - Mayo Clinic News Network

    ), a concentrated dose of healing platelet cells that exist in the patient's blood. In a recent study published in Physical Medicine & Rehabilitation, Mayo ...

  5. Aneurysm Treatment Using Flow Diverter - Clinical Trials

    ... platelet activation, and thrombin generation with outcomes and to compare circulating miRNA and protein profiles and computational fluid dynamic (CFO) based ...

  6. Physical Medicine and Rehabilitation - Doctors - Mayo Clinic

    Jane Konidis, M.D.. Physiatrist. Rochester, MN. Areas of focus: Ultrasound, Nerve hydrodissection, Platelet rich plasma injection, Bone marrow aspirate ...

  7. Neurology - Clinical trials

    ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection. Pagination Clinical studies. PrevPrevious Page · Go to page 77 · Go to page 8 ...

  8. Neurology - Clinical trials - Mayo Clinic

    ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection. A Study to Evaluate MR of CSF Dynamics. Rochester, Minn. The purpose of ...

  9. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

    - Platelet count ≥ 75 x 10^9/L without the assistance of thrombopoietic ... - Platelets > 600 × 10^9/L - Resistant or intolerant to HU Exclusion ...

  10. Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) - Mayo Clinic

    Platelet count > 600 × 10^9/L after 3 months of at least 2 g/day of hydroxyurea (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's ...